Key facts
- It has raised $87.5M; the latest was Early Stage VC ($33.5M) in Aug 2025.
- Notable investors include Gaingels, 8VC, Calm Ventures, Korea Development Bank, Samsung Venture Investment — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Latus Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Latus Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Latus Bio
Developer of curative medicines designed for neurological diseases. The company specializes in novel non-human primate-based discovery approaches, enabling doctors to deliver therapeutic genes to targeted cells with increased substructure- and cell-specific targeting in the central nervous system.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2022
- Employees
- 31
- Website
- latusbio.com/
- Ownership
- Privately Held (backing)
Latus Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Latus Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Latus Bio in its N-PORT filings yet. We sweep new filings monthly.